Updated October 1, 2026
The average analyst price target for Xeris Pharmaceuticals is $12.29 on a 12-month horizon. With the stock trading at $9.57, that leaves upside of +28.5%.
We define the fair-value range as ±10% of the price target, because price targets are estimates, not exact values. For Xeris Pharmaceuticals the range runs from $11.06 to $13.52 — which means the stock is considered undervalued.
The average analyst price target for Xeris Pharmaceuticals is $12.29 on a 12-month horizon. The current price is $9.57, which leaves upside of +28.5%. On that basis the stock is considered undervalued.
The fair-value range (±10% of the price target) for Xeris Pharmaceuticals runs from $11.06 to $13.52. The price currently sits below the range – the stock is considered undervalued.
A price target is the analysts' estimate of where the stock could be in 12 months – not a promise. Analysts often adjust their targets only after the price has already moved, so big turning points are sometimes missed. Use the price target as a reference point together with the technical signal as well as the key figures – never as a guarantee.
The price target is the average of the analysts' 12-month price targets (Wall Street consensus), refreshed daily from our data sources – together with the price, the signal, plus the key figures.
The price target is the average of the analysts' 12-month price targets (Wall Street consensus), updated daily. Analysis framework by Troels Højbjerg, the creator of WallStreetBuys. WallStreetBuys does not offer investment advice – trading stocks carries a risk of losses.